FDA approves bipolar depression treatment for broad range of adults
December 21, 2021Manufacturing and Production
Intra-Cellular Therapies, a biopharmaceutical company focused on the development and commercialisation of therapeutics for central nervous system (CNS) disorders, have …
Vifor Pharma announces positive results from Phase IIIb trial of heart failure treatment
December 21, 2021Medical Communications
Vifor Pharma has announced positive findings for the completed Phase IIIb DIAMOND trial of Veltassa, in heart failure patients with …
Positive CHMP opinion for sickle cell disease anaemia tablet
December 20, 2021Sales and Marketing
Global Blood Therapeutics (GBT) have announced the CHMP adopted a positive opinion recommending marketing authorisation for Oxbryta® (vocelotor) tablets. Oxbryta …
FDA approval of Tezspire for severe asthma
December 20, 2021Sales and Marketing
Tezpire (tezepelumab-ekko), manufactured by AstraZeneca and Amgen, has been approved in the US for the add-on maintenance treatment of adult …
Study reveals potential link between COVID-19 and Parkinson’s Disease
December 20, 2021Sales and Marketing
Scientists in The Netherlands have detailed a possible correlation between COVID-19 and the onset of Parkinson’s disease. The findings may …
New COVID-19 drug Sotrovimab becomes available on NHS
December 20, 2021Sales and Marketing
Sotrovimab, commercially known as Xevudy, is now available on the NHS to reduce the risk of vulnerable patients needing hospitalisation …
CDC recommends mRNA vaccines over J&J
December 17, 2021Medical Communications
The CDC has recommended Pfizer-BioNTech and Moderna COVID-19 vaccines over Johnson & Johnson jabs. The recommendation from CDC Director Dr …
COVID-19 booster vaccine triggers immune response in days, not weeks, scientists say
December 17, 2021Medical Communications
COVID-19 booster jabs trigger an immune response in a matter of days, rather than weeks, scientists have shared. Data suggests …
NICE recommends offering PrEP to those at high risk of HIV
December 17, 2021Medical Communications
People at the highest risk of catching HIV should be offered Pre Exposure Prophylaxis (PrEP), NICE has recommended for the …
Omicron grows 70 times faster than Delta in bronchial tissue
December 16, 2021Business Services
The COVID-19 variant, Omicron, has been found to replicate around 70 times faster than the original and Delta variants of …
Potential drugs for AMD treatment identified using stem-cell based research
December 16, 2021Business Services
Researchers at the National Institutes of Health (NIH) have identified two drug candidates to slow dry age-related macular degeneration (AMD), …
FDA pauses several trials of Merck’s investigational HIV drug
December 16, 2021Business Services
The FDA has placed holds on several clinical trials for the oral and implant formulations of investigation drug islatravir (MK-8591), …
European Commission backs Johnson & Johnson COVID-19 booster for adults
December 16, 2021Business Services
The EC has recommended a booster dose of Johnson & Johnson’s COVID-19 vaccine at least two months after a first …
Pfizer shares efficacy of COVID pill: near 90% protection against hospitalisation
December 15, 2021Research and Development
Pfizer have announced that a final analysis of the antiviral pill Paxlovid (nirmatrelvir tablets and ritonavir tablets) shows 89% reduction …
Bionaut Labs and Candel Therapeutics collaborate to deliver immunotherapies
December 15, 2021Research and Development
Bionaut Labs, and Candel Therapeutics, have announced a strategic collaboration to investigate the use of Bionaut’s remote-controlled microscale robots for …
Positive results in Phase III trial of candidemia and invasive candidiasis
December 15, 2021Research and Development
Cidara Therapeutics and Mundipharma have announced positive topline data from the ReSTORE Phase III clinical trial, evaluating the efficacy and …
Sanofi and GSK announce positive booster data for COVID-19 vaccine candidate
December 15, 2021Research and Development
Sanofi and GSK have announced positive preliminary booster data for their COVID-19 vaccine candidate, and continuation of their Phase III …
European Commission approves Pfizer drug for adults with moderate-to-severe atopic dermatitis
December 14, 2021Manufacturing and Production
The EC has approved the investigational once-daily Janus kinase 1 (JAK1) inhibitor, abrocitinib, for the treatment of moderate-to-severe atopic dermatitis …
India’s Serum Novavax jab to be launched for children in six months
December 14, 2021Medical Communications
The Serum Institute of India (SII) plans to launch the Novavax COVID-19 vaccine for children in the country in six …
Phase III trial results gives hope to B-Cell lymphoma patients
December 14, 2021Manufacturing and Production
Bristol Myers Squibb (BMS) reported that interim assessment data from the Phase III TRANSFORM clinical trial of Breyanzi (lisocabtagene maraleucel; …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
